Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lindsey Steglich

Physician Assistant, Medical Susanville, CA Physician Assistant

NPI 1538573365 CMS profile 10590822

1850 Spring Ridge Dr, Susanville, CA 96130

Open in the dashboard

General payments

$21,640

291 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsey Steglich of Susanville, CA is reported in the CMS Open Payments database as having received $21,640 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,279 70
2024 General $687 39
2023 General $5,548 106
2022 General $3,023 53
2021 General $11,104 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsey Steglich
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Lindsey Steglich were reported at $1,279. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Lindsey Steglich Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $11,104 $156 $41–$563 $132
2022 $3,023 $185 $55–$649 $149
2023 $5,548 $199 $58–$717 $160
2024 $687 $206 $62–$740 $164
2025 $1,279 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Organon LLC $11,773 21 payments
  2. Merck Sharp & Dohme Corporation $4,920 18 payments
  3. AbbVie, Inc. $950 53 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $817 56 payments
  5. Novo Nordisk Inc $813 30 payments
  6. Daiichi Sankyo Inc. $418 23 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $233 8 payments
  8. Pfizer Inc. $208 10 payments
  9. Lilly USA, LLC $194 7 payments
  10. AstraZeneca Pharmaceuticals LP $179 5 payments
  11. Other $1,137 60 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,975 9 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $5,737 7 payments
  3. Food and Beverage $5,183 266 payments
  4. Travel and Lodging $746 9 payments
Products named General payments · program years 2021–2025
  1. Nexplanon Womens Health $5,986 10 payments
  2. NEXPLANON Etonogestrel $5,780 10 payments
  3. NEXPLANON Womens Health $4,734 8 payments
  4. XIFAXAN $817 56 payments
  5. RYBELSUS $672 25 payments
  6. UBRELVY $556 35 payments
  7. Ozempic $488 24 payments
  8. INJECTAFER $418 23 payments
  9. VRAYLAR $321 12 payments
  10. QULIPTA $295 22 payments
  11. Other $2,740 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

234

Median for Physician Assistant: 241

Drug cost

$1,790

Median for Physician Assistant: $4,110

Branded share of claims

15%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Albuterol Sulfate Hfa Albuterol Sulfate Brand 20 $608
Gabapentin Generic 15 $148
Hydroxyzine Hcl Generic 12 $146
Amlodipine Besylate Generic 19 $135
Lisinopril Generic 26 $127
Doxycycline Hyclate Generic 18 $117
Fluticasone Propionate Generic 17 $115
Losartan Potassium Generic 17 $98
Atorvastatin Calcium Generic 17 $98
Prednisone Generic 33 $88

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INJECTAFER
  • Daiichi Sankyo Inc. $170
$170 — —
VRAYLAR
  • AbbVie, Inc. $90
$90 — —
UBRELVY
  • AbbVie, Inc. $54
$54 — —
QULIPTA
  • AbbVie, Inc. $36
$36 — —
Otezla
  • Amgen Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record